Moneycontrol
HomeNewsBusinessMarketsClosing Bell: Nifty ends below 18,000, Sensex down 317 pts; realty, metal, IT, banks worst hit

Closing Bell: Nifty ends below 18,000, Sensex down 317 pts; realty, metal, IT, banks worst hit

Except capital goods, all other sectoral indices ended in the red.

February 17, 2023 / 16:25 IST
Story continues below Advertisement

February 17, 2023 / 16:16 IST

Amol Athawale, Deputy Vice-President - Technical Research, Kotak Securities

Markets witnessed turbulence on the back of weak global cues as investors booked profit in banking, IT and telecom stocks. Rising inflation, US bond yields, and dollar index are once again creating a lot of uncertainty amongst the investors.

For the bulls, 17,900-17,800 or 20-day SMA would act as a key support zone while 50-day SMA or 18,100 and 18,200 could be the immediate hurdle.

On the flip side, the selling pressure could accelerate if the index slips below 17,800 and in case of further correction, it could slip to 17,700-17,650.

Story continues below Advertisement
February 17, 2023 / 16:09 IST

Kunal Shah, Senior Technical Analyst at LKP Securities

The Bank Nifty index on the daily chart witnessed a breakdown with a rise in volumes. The index remains in a sell mode as long as it sustains below the level of 41500.

The index immediate support stands at 41000 and if it fails to sustain it on a closing basis will accelerate the downside move towards 40,000 levels.

February 17, 2023 / 15:58 IST

Dilip Parmar, Research Analyst, HDFC Securities

Indian rupee marked the fourth weekly decline in a row following hawkish comments from Federal Reserve members that supported the dollar bulls. However, the rupee relatively better performed among the Asian currencies amid the central bank’s intervention. The local unit manages to float above 83 for the time being on the back of the bargain buying of domestic equities by foreign institutions.

Though the rupee manages to stay above 83, it might be difficult to hold it for long amid broad-based strength in the greenback.

Technically, spot USDINR has resistance at 83.10 and support at 82.30.

February 17, 2023 / 15:50 IST

Vinod Nair, Head of Research at Geojit Financial Services

Lack of major triggers in the domestic market is attracting global cues to dictate the market trend. The US market is facing an unfavourable combination of higher-than-expected inflation and a stronger job market.

The PPI (Producer Price Index) in the US came in at 6.0%, in contrast to the expectation of 5.4%. This suggests that interest rates have not yet peaked and will remain elevated for a long period.

Story continues below Advertisement
February 17, 2023 / 15:40 IST

Rupak De, Senior Technical Analyst at LKP Securities

The Nifty has fallen to the upper band of the falling channel on the daily chart. The trend for the near term is likely to remain sideways to positive as long as it remains above the falling channel.

A recovery towards the higher level will likely happen if the bulls manage to hold the Nifty above 17,880. On the higher end, however, 18,150 is likely to act as resistance.

February 17, 2023 / 15:33 IST

Rupee Close:

Indian rupee ended 12 paise lower at 82.83 per dollar against previous close of 82.71.

February 17, 2023 / 15:30 IST

Market Close:

Benchmark indices broke three-day winning streak and ended lower with Nifty below 18,000.

At Close, the Sensex was down 316.94 points or 0.52% at 61,002.57, and the Nifty was down 91.60 points or 0.51% at 17,944.20. About 1468 shares have advanced, 1893 shares declined, and 136 shares are unchanged.

Adani Enterprises, IndusInd Bank, Nestle India, SBI Life Insurance and HDFC Lifewere among the major lowers on the Nifty, while gainers included L&T, UltraTech Cement, BPCL, Asian Paintsand Coal India.

Except capital goods, all other sectoral indices ended in the red.

The BSE midcap index fell 0.7 percent and smallcap index down 0.20 percent.

February 17, 2023 / 15:25 IST

Morgan Stanley View on Nestle India

Brokerage house kept an underweight rating on the stock with a target price of Rs 15,315 per share.

The Q4 results of the company were below expectations on the top line, but they were ahead on margin.

The firm remained underweight on the stock due to margin pressure, likely mix deterioration, and relative valuation.

February 17, 2023 / 15:21 IST

Credit Suisse View on Dr Reddy’s Laboratories

Underperform rating, target at Rs 4,100 per share
Indivior expects launch of Suboxone by Apotex in Q1FY24
Suboxone still constitutes about 7% of company’s base EBITDA
Entry of Apotex can potentially impact 2/5th of its EBITDA from Suboxone
EBITDA from Suboxone can decline by 40%, or 3% of consolidated EBITDA

Dr Reddy's Laboratories was quoting at Rs 4,509.55, down Rs 8.80, or 0.19 percent on the BSE.

Story continues below Advertisement